Clinical Trial Update: Comparison of 24 Hour Bronchodilator Efficacy of Tiotropium 18 mcg Delivered Via DISCAIR Versus SPIRIVA 18 µg Delivered Via HANDIHALER® in Patients With Moderate to Severe COPD [Phase 4]

View source ↗

Summary

Phase 4 trial comparing 24-hour bronchodilator efficacy of tiotropium delivered via DISCAIR versus HANDIHALER in moderate to severe COPD.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Tiotropium DISCAIR (tiotropium)
• Tiotropium HandiHaler (tiotropium)

Snippet

Sponsor: Neutec Ar-Ge San ve Tic A.Ş | Conditions: COPD | Phase 4 | Status: COMPLETED